daratumumab + carfilzomib + lenalidomide + dexamethasone

The combination of **daratumumab + carfilzomib + lenalidomide + dexamethasone** is a four-drug regimen used in the treatment of multiple myeloma, particularly in newly diagnosed or relapsed/refractory settings[2][4][7]. - **Daratumumab** is a monoclonal antibody that targets the CD38 protein on myeloma cells, leading to cell death[4][6]. - **Carfilzomib** is a second-generation proteasome inhibitor that irreversibly binds and inhibits the chymotrypsin-like activity of the 20S proteasome, resulting in cell cycle arrest and apoptosis[1][3][4]. - **Lenalidomide** is an immunomodulatory agent that enhances the body's immune response against tumor cells and inhibits angiogenesis[4]. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties[4]. This regimen is associated with high response rates and durable minimal residual disease (MRD) negativity, especially in patients with newly diagnosed and high-risk cytogenetic features[2][7]. It is typically administered by intravenous (daratumumab, carfilzomib) and oral (lenalidomide, dexamethasone) routes.

Brand names

KyprolisRevlimidDarzalex

Other names

dara-KRd